#Germany #Oberkochen #Revolune #Multiplex Assays #Concept Life Sciences

Revolune and Concept Life Sciences Partnership

Revolune, a notable player in the life sciences sector, has recently announced their collaboration with Concept Life Sciences aimed at transforming the way biopharma and life sciences entities conduct multiplex immunofluorescence assays. This partnership seeks to facilitate the transition of existing workflows to more flexible, adaptable formats that can meet the evolving demands of the industry.

A Growing Need for Flexibility

As the field of biomarker research evolves, there is an increasing necessity for techniques that can adapt to various research needs. Traditional workflows often restrict researchers, making it challenging to employ innovative strategies in tissue biomarker exploration. Recognizing this, Revolune has expanded its offerings to include support for 4- to 7-plex assays, which are becoming crucial for those looking to maximize their research effectiveness.

Adrian Arechiga, the Chief Commercial Officer at Revolune, emphasized that many researchers are not approaching this transition without prior knowledge; they possess established assays and panels that are vital for their work. The introduction of Revolune’s flexible staining technologies provides a crucial bridge for these teams, allowing them to retain their existing knowledge while transitioning to potentially superior workflows.

Concept Life Sciences: A Key Player

Concept Life Sciences is renowned for their extensive expertise in contract research, particularly within the realms of translational biology and assay development. This collaboration leverages their strengths in analytical services and biomarker discovery, which are instrumental for clients eager to transfer their established assays onto Revolune’s innovative platform. The aim is to not only support current organizational structures but also enhance the operational capabilities of clients by simplifying the assay transfer process.

This partnership marks a significant step towards enabling research teams to optimize their panel designs and effectively execute tissue staining workflows. It will allow researchers to connect biomarker data with broader discovery programs, thereby improving the efficacy and speed of their research efforts.

Implementation and Client Benefits

Both companies have outlined a clear vision regarding the transition process. Clients can start by assessing the feasibility of transferring their existing assays, then they can work closely with Concept Life Sciences to optimize their new workflow designs. The expected outcome is a smoother implementation of multiplex formats that not only meet the rigorous standards of scientific research but also provide flexibility for future developments.

Adam Davenport, the Chief Scientific Officer at Concept Life Sciences, expressed enthusiasm about partnering with Revolune, highlighting their joint mission to aid clients in re-evaluating their approaches to multiplex tissue analysis. The primary goal remains to facilitate the transfer of current assays while exploring innovative panel opportunities as well as utilizing multiplex immunofluorescence for making informed, translational decisions.

Meeting at SITC 2026

Furthermore, both organizations will be participating in the Society for Immunotherapy of Cancer (SITC) Annual Meeting set for November 4th to 8th, 2026, in Phoenix, Arizona. They will host an evening gathering to interact with attendees, share insights, and discuss how they plan to drive innovation in the research sphere through their partnership. This event presents a unique opportunity for researchers to connect with both teams and learn firsthand how these advancements can benefit their specific areas of focus.

Conclusion

The collaboration between Revolune and Concept Life Sciences is poised to usher in a new era of flexibility and efficiency in the biopharma and life sciences sectors. By integrating their capabilities, the organizations aim to facilitate more streamlined research processes and ultimately advance the discovery of critical biomarker insights. The evolving landscape of life sciences demands such collaborations to meet the growing expectations of researchers, making this partnership a vital step in supporting scientific advancements across the industry.